Moreover, the molecular mechanisms and applications of STING agonist‐based combination therapies are discussed, including synergistic strategies with chemotherapy, radiotherapy, immunotherapy (e.g., immune checkpoint blockade (ICB), indoleamine 2,3‐dioxygenase (IDO) inhibitor, cancer vaccine, adoptive cell therapy (ACT)), phototherapy, sonodynamic therapy (SDT), and targeted therapy. The gene discussed is IDO2; the disease is cancer.